

# Welcome

# Full Year 2024 results announcement

We will be starting at 9:00am








# Full year results presentation

12 months ended31 December 2024









- **01** Overview
- **02** Market Unit performance
- **03** Financial review
- **04** Solvency, Funding and Investments
- **05** Sustainability and ESG
- **06** Outlook

**07** Q&A



James Lenton Group Chief Financial Officer



Clare Binmore
Group Performance
Director



**Gareth Evans**Group Treasurer

# Bupa overview



James Lenton Group CFO



# **Group financial highlights**

£16.9bn

+12% at AER, FY 2023: £15.1bn

**Revenue** +16% at CER, FY 2023: £14.6bn

£914m

Underlying profit before tax

+59% at CER, FY 2023: £576m +53% at AER, FY 2023: £599m £972m

Statutory profit before tax

+72% at AER, FY 2023: £564r

£1.3bn

Net cash generated from operating activities +7% at AER, FY 2023: £1.2bn 176%

Solvency II coverage ratio<sup>1</sup> FY 2023: 175%

<sup>1.</sup> The FY 2024 Solvency II capital position is an estimate and unaudited.

### **Delivering our 3x6 Strategy Our three ambitions**

The ambitions Year-end position<sup>1</sup> Overall progress in 2024



40% customer care touchpoints owned by Bupa1

25.9%

We owned 25.9% of our customer care touchpoints, having significantly expanded our digital health offerings (via Blua<sup>3</sup>) and our physical provision network.

+3.7 ppts

We increased the percentage of customer care touchpoints that we own in the majority (92%) of funding BUs. The average improvement was +3.7 ppts per BU.



60% active digital customers<sup>1</sup>

46.1%

We ended the year with 46.1% of our funding customers actively engaging with us through digital channels, having successfully increased customer awareness and adoption of Blua<sup>3</sup>.

+5.8 ppts

We grew our active digital customer base in every funding BU. The average improvement was +5.8 ppts per BU.



★★ 80 Net Promoter Score<sup>1, 2</sup> **67 NPS** 

By the end of the year, we achieved an average NPS score of 67, having delivered over 10,500 customer experience improvements to key parts of the customer journey.

**+5 NPS** 

We improved NPS in the majority (92%) of BUs. The average improvement was +5 NPS points per

<sup>1.</sup> To maximise Impact, the 40 Ambition is focused on Bupa's three largest Insurance BUs (in Australia, the UK and Spain) and the year end position represents the true average. The 60 Ambition is focused on Bupa's funding BUs and the year end percentage is based on a simple raw average. The 80 Ambition is relevant to all BUs and the year end scope is based on a simple raw average. 2. NPS is derived from multiple transactional NPS Surveys. 3.Blua and equivalent digital solutions.

# Examples of progress against our strategy in FY24 Our six strategic and enabling pillars

#### **Customers**

We implemented over 10,500 customer experience improvements (+31% vs. 2023). The majority (92%) of BUs improved their NPS.



#### Growth

We have over **60.5m** customers<sup>1</sup> worldwide (+21% vs. 2023).

A key driver of insurance customer growth has been **Niva Bupa**, our health insurance business in India.



#### **Transformation**

Almost **7.5m** customers are using Blua<sup>2</sup> (+36% vs. 2023), benefiting from a network of more than **16.700** clinicians.



#### **Sustainability**

Our Healthy Cities challenge unlocked £3.5m for nature-related investments in 68 cities.





#### **Agile Culture**

We listened to over **81,000** customer feedback videos and calls (+33% vs.2023), and generated **39,000** ideas to improve the customer experience (+66% vs.2023).



#### Data

We are driving better, data-driven decisions across Bupa by upskilling our people, with **16,000** employees using data from our platforms (+33% vs. 2023).

2. Or an equivalent digital solution

<sup>1.</sup> Customer counting methodologies vary between business units, and in certain business units customers are counted more than once if they choose to purchase or utilise multiple products or services as part of our connected care offering.

# Looking forward: Our purpose, values and ambition

#### **Purpose**



Helping people live longer, healthier, happier lives and making a better world



#### **Values**

Brave
Caring
Responsible



#### **Ambition**

To be the world's most customer-centric healthcare company

Bupa's purpose, values and ambition are **long-term elements of our strategy** that have served us well over the last three years under the 3x6 Strategy.

Looking ahead to our **new strategic era (2025-27)** these elements will remain constant and **continue to guide our decisions and actions**:

- Our **purpose** is core to everything we do at Bupa, it captures why Bupa exists and the impact we want to have in the world;
- Our **values** define our culture empowering us to stand up for what's right for our customers, residents, patients and for each other;
- Our ambition reflects our commitment to excellent customer experience, through great service and value, frictionless access and quality healthcare.

# Our new strategy for 2025-27 The 3x100 Strategy



Three Ambition KPIs



Ensure we continue raising the bar for customer-centricity across Bupa



Use clinical data to understand customer health needs and create more personalised care journeys



#### 100m Customers supported by Bupa

Innovate and grow our services to deliver high-quality healthcare to more people than ever before



**Supporting** 

**Pillars** 



Customer: 500 customer experience improvements per Business Unit per year



Cloud: Accelerated migration of systems to the Cloud



**Connected Care:** All Business Units delivering against Connected Care Strategies

# Market Unit performance



James Lenton Group CFO



### **Bupa Asia Pacific**

Customer growth driving financial performance across all business units

- Grew customers across insurance (9<sup>th</sup> quarter of maintaining or growing market share<sup>1</sup> in Aus.) and provision
- Aged care occupancy increased to 95%<sup>2</sup> in BVAC Australia (6-year high) and 94%<sup>2</sup> in New Zealand
- All business units improved NPS scores
- Over 3,000 customer experience improvements implemented
- Year on year revenue and profit growth impacted by a significant reduction in the cost of returning COVID-19 claims savings to Australia Health Insurance customers relative to 2023
- Revenue increased by 8% excluding the return of COVID-19 claims savings
- Underlying Profit growth excluding cost of returning COVID-19 claims savings was primarily attributable to Australia Health Services, Australia and New Zealand Aged Care and Hong Kong

#### Revenue

£6.3bn

+10% AER, FY 2023: £5.7bn +13% CER, FY 2023: £5.5bn

#### **Underlying profit**

£446m

+190% AER, FY 2023: £154m +201% CER, FY 2023: £148m

### Combined operating ratio


Bupa HI Pty Ltd (Australia)

COR impacted by a reduction in COVID-19 claims savings returned to customers in 2024 relative to 2023



#### Revenue by business

- A. Bupa Health Insurance 70%
- B. Bupa Health Services 11%
- C. Bupa Villages and Aged Care Australia 7%
- **D.** Bupa Villages and Aged Care New Zealand 3%
- E. Hong Kong Insurance 5%
- F. Hong Kong Health Services 4%



<sup>1.</sup> Source: APRA industry data for domestic market share up to 31 December 2024; 2. Closing occupancy

### **Europe and Latin America**

Strong growth across insurance and provision as we continue to grow our provision footprint in line with our connected care strategy

- Grew customers across insurance and provision
- Aged care occupancy in Spain remained high at 95%<sup>1</sup>
- Improved NPS scores across the majority of business units
- Implemented around 4,800 customer experience improvements
- Announced plans to open 2 new hospitals in Spain and completed the acquisition of 1 in Poland
- Strong revenue and profit growth driven by the increase in customer numbers whilst profit also benefited from higher investment returns

#### Revenue

£5.4bn

+7% AER, FY 2023: £5.1bn +13% CER, FY 2023: £4.8bn


#### **Underlying profit**

£442m

+25% AER, FY 2023: £355m +30% CER, FY 2023: £340m


#### **Combined operating ratio**

Sanitas S.A. de Seguros (Spain)



#### **Revenue by business**

- A. Sanitas Seguros 30%
- B. Sanitas Dental 4%
- C. Sanitas Hospitals and New Services 3%
- D. Sanitas Mayores 3%
- E. Bupa Chile 18%
- F. LuxMed (Poland) 18%
- G. Bupa Acıbadem Sigorta (Türkiye) 8%
- H. Care Plus (Brazil) 7%
- I. Bupa Mexico 5%
- J. Bupa Global Latin America (BGLA) 4%



<sup>1.</sup> Closing occupancy

### Bupa Global, India & UK

Strong revenue and customer growth driven by UK Insurance whilst we completed the acquisition of a controlling stake in Niva Bupa

- Customer volumes increased across both insurance and provision
- UK Aged care occupancy increased to 91%<sup>1</sup>
- Improved NPS scores across all business units
- Over 2,600 customer experience improvements implemented
- Increased investment in Niva Bupa to 56%
- Excluding the consolidation of Niva Bupa, revenues increased by 11% driven by strong customer growth
- Underlying profit reduced driven by the impact of fair value adjustments on the Niva Bupa acquisition and the timing of the return of premium provision release in the prior year driving reduction in UK Insurance profit
- UK Dental and Health Services returned to profitability in the year

#### Revenue

£5.2bn


+22% AER, FY 2023: £4.2bn +22% CER, FY 2023: £4.2bn

#### **Underlying profit**

£228m


(15)% AER, FY 2023: £269m (15)% CER, FY 2023: £269m

#### Combined operating ratio Bupa Insurance Ltd (UK)



#### **Revenue by business**

- A. UK Insurance 48%
- B. Bupa Global 19%
- C. Niva Bupa 9%
- D. Bupa Dental Care 10%
- E. Care Services 10%
- F. Health Services 4%



Full year 2024 results presentation 1. Closing occupancy.

### **Other businesses**

Comprised of our associate insurance and provision businesses in Saudi Arabia. Niva Bupa now forms part of the Bupa Global, India and UK Market Unit after Bupa took a controlling stake.

#### Saudi Arabia

 Underlying profit of £97m was up 17%<sup>1</sup> at CER largely driven by higher volumes, margins and increased investment returns in Bupa Arabia.

<sup>1</sup>From 2024, Niva is reported as a fully consolidated subsidiary within the Bupa Global, India & UK Market unit. 2023 comparative remains calculated including Niva Bupa result.



# Financial Review




Clare Binmore Group Performance Director



### **Financial overview**

#### Revenue




- Revenue increased by 16% at CER (10% when excluding Niva Bupa and COVID-19 claim savings).
- Health insurance revenue grew by 11%2 driven by strong customer growth.
- · Health provision revenue increased by 10% driven by higher levels of activity.
- Aged care revenue increased by 10% driven by 2ppt increase in closing occupancy to 94%.

#### Underlying profit before taxation<sup>1</sup>



- Underlying profit increased by 59% at CER.
- · Health insurance growth driven by higher revenues, investment returns and significant reduction in the net cost of COVID-19 claim savings returned to customers in Australia Health Insurance.
- · Health Provision grew driven by strong customer growth.
- Aged care increased from higher revenues and margin improvement.
- Central cost increase driven by global capability investment (including ESG) and higher staff costs.

#### Combined operating ratio (COR)<sup>3</sup>



 1ppt improvement in Group COR driven by Australia Health Insurance, partially offset by the loss in Niva Bupa and the timing of the UK Insurance return of premium release in the first half of 2023.

<sup>1.</sup> Underlying profit is a non-GAAP financial measure. This means it is not comparable to other companies. Underlying profit reflects our trading performance and excludes a number of items included in statutory profit before taxation, to facilitate period on period comparison. A reconciliation to statutory profit before taxation can be found in the notes to the financial statements; 2. Excluding Niva Bupa and the return of COVID-19 claims savings in Australia Health Insurance; 3. COR of the main insurance 45 businesses: Australia Health Insurance 93% (2023: 98%); Bupa Insurance Ltd 96% (2023: 95%); and Sanitas Seguros 90% (2023: 89%)

## Statutory profit before taxation

Statutory profit before taxation increased by £408m¹ to £972m driven by the increase in underlying profit and positive variance in non-underlying items

	(AER) £m	(AER) £m
Underlying profit before taxation at AER	914	599
Impairment of intangibles and goodwill arising on business combinations	(2)	(1)
Niva Bupa <sup>2</sup> fair value gain on pre-existing shareholding	309	-
Chile payment plan payable	(187)	-
Short-term fluctuation on investment returns	(9)	31
Net loss on disposal of businesses and transaction costs on business combinations	(26)	(1)
Net property revaluation gains/(losses)	9	(21)
Realised and unrealised foreign exchange gains	10	2
Amortisation of bed licences	(13)	(32)
Other non-underlying items	(33)	(13)
Total non-underlying items	58	(35)
Statutory profit before taxation	972	564

<sup>1</sup> AFR

<sup>2.</sup> A gain of £62m was also recognised in equity in November from the new capital raise and partial sale of our existing shares on IPO.


# Solvency, Funding and Investments




Gareth Evans
Group Treasurer




Clare Binmore Group Performance Director



# Solvency<sup>1</sup>





- SII coverage has increased slightly from FY 2023 with strong underlying business performance.
- The Group continues to maintain a strong capital position above the working range of 140% 170%.
- Our capital coverage is largely unaffected by market risk sensitivities due to our investment management approach.
- Property (mainly care homes, hospitals and clinics) remains the most sensitive risk to our capital coverage.


#### **Risk sensitivities**

Solvency Coverage Ratio	176%
Property values - 10%	166%
Loss ratio worsening by 2%	168%
Sterling depreciates by 20%	170%
Group specific parameter (GSP) <sup>2</sup> +0.2%	173%
Credit spreads + 100bps assuming no credit transition	175%
Interest rate +/- 100bps	175%
Equity markets - 20%	175%
Pension risk + 10%	176%
	- 

- The FY 2024 Solvency II capital position, SCR and coverage ratio are estimates and unaudited:
- Group Specific Parameter (GSP) is substituted for the insurance premium risk parameter in the standard formula, reflecting the Group's loss experience;
- Lower end of our Group target capital working range.

# Solvency<sup>1</sup>

#### Movement in Solvency II capital surplus, £m



<sup>1.</sup> The FY 2024 Solvency II capital position, SCR and coverage ratio are estimates and unaudited; 2. Operating capital of £680m includes adjusted IFRS comprehensive income, reflecting SII valuation differences and the reclassification of non-operating items; 3. Niva Acquisition and IPO includes £220m decrease in solvency capital surplus from the Niva Acquisition partly offset by £90m increase from the Niva IPO primarily due to capital raised from the IPO and our sale of 2.6% of our stake in Niva.


## **Funding**

Leverage ratio<sup>1,2</sup>


#### Fitch rating upgraded and leverage and liquidity remain well positioned



### Leverage ratio when accounting for IFRS 16 lease liabilities<sup>2</sup>



#### **Debt maturity profile**



- At 31 December 2024, our £900m Revolving Credit Facility (RCF) was undrawn (2023: undrawn).
- Leverage down to 16.0%.
- In October, Fitch upgraded the Bupa Finance plc Issuer Default Rating to A from A- with Stable outlook and upgraded the related bond ratings.

#### **Ratings**

A3
Moody's senior debt rating stable


Fitch senior debt rating stable

- Bupa Finance plc Senior
- Bupa Finance plc Tier 2 Subordinated
- Bupa Finance plc RT1 Subordinated<sup>3</sup>
- Bank Facilities

1. Leverage is calculated based on gross debt (excluding RT1) divided by gross debt plus equity.

- 2. FY 2022 onward shown on a restated IFRS 17 basis.
- 3. Perpetual notes with a 2032 call date.

### Financial investments overview




- Investment strategy remains conservative focussed on high credit quality and liquid assets.
- Asset allocation heavily weighted to cash and floating rate instruments. We also hold corporate and government bonds within certain insurance businesses (the majority of which are considered to be cash and cash like instruments).
- Portfolio includes full consolidation of Niva Bupa cash & investments, which increases the global level of government and corporate bond holdings.
- Increase in financial income on cash and investments across all Market Units compared to FY 2023, supported by volume growth and global interest rates remaining at elevated levels.

<sup>&</sup>lt;sup>1</sup> Restricted assets are cash deposits held in respect of a charge over unfunded pension scheme obligations and also held in respect of claims funds held on behalf of corporate customers.
<sup>2</sup> Certificate of Deposit (CDs) and Commercial Paper (CP)


# Sustainability and ESG





# Making a better world: Sustainability & ESG

Our sustainability strategy focuses on the link between the health of the planet and the health of people, and how Bupa can make healthcare more sustainable. A review of the sustainability strategy is currently being undertaken to align with the 2025-2027 Strategy.



#### **Our Foundations**

Strong action on wider ESG topics, including inclusion and diversity, responsible business conduct, social impact, governance and transparency

### **Sustainability progress**

#### **Healthy Cities**

Last year, our programme supported over 500,000 participants, unlocking £3.5m for nature-related investments in 68 cities.



# **Eco-Disruptive Programme**

We refocused our **eco-Disruptive programme** to help those in society who face barriers to accessing quality healthcare and services.





#### **Renewable Energy**

Globally **94%** of our electricity consumption came from renewable sources (91%: 2023).




# Contribution to our local communities

We invested £14.3m in our local communities (including over £5.4m through the Bupa Foundations).

# Outlook



James Lenton Group CFO



### **Outlook**

While we have made significant progress, we know there is still more we can achieve. That's why we've launched our new strategy for 2025-27 which is designed to be an evolution and acceleration of our current 3x6 strategy.

We must stay focused on the work we've been doing over the past three years, while maintaining our relentless dedication to providing a world-class customer experience and continuing to build our data and digital capabilities.

The macro-economic, political and regulatory outlook continues to be uncertain, but we remain confident for the future. We are well-placed to navigate challenges and take opportunities because of our underlying financial strength, resilience and diversified business model.





# Q&A



James Lenton Group CFO



Clare Binmore Group Performance Director



**Gareth Evans**Group Treasurer

# **Further information**

Website www.bupa.com/financials

ir@bupa.com

# Appendix



# **History and footprint**



We are an international healthcare company serving over 60 million customers worldwide.

Established in 1947, Bupa's **purpose is helping people live longer, healthier, happier lives and making a better world.** With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers.

Bupa has businesses around the world, principally in Australia, the UK, Spain, Poland, Chile, Hong Kong SAR, India, Türkiye, Brazil, Mexico and New Zealand. We also have associate businesses in Saudi Arabia.



#### **Ambition**

To be the world's most customer-centric healthcare company

#### **Purpose**

Helping people live longer, healthier, happier lives and making a better world.



#### **Values**

#### **Brave**

Make new possibilities happen

#### **Caring**

Act with empathy and respect

#### Responsible

Own your decisions and actions



#### **Business Model**

Bupa's businesses and operations are tailored to local market conditions, healthcare systems and customer needs. We specialise in:

Health Insurance38m customers12.3bn revenue

Provision
23m customers

3.3bn revenue

Aged Care
21k residents
1.3bn revenue

# **Bupa around the world**

		Bupa Asia Pacific			Europe and Latin America						Bupa Global, India and UK			U Other	
		Australia	New Zealand	Hong Kong		Poland	Türkiye	Chile	Brazil	Bupa Global Latin America	Mexico	United Kingdom	India	Bupa Global¹	I I I I Saudi II Arabia <sup>2</sup>
Funding	Health insurance	•													
	Health subscription														lj lj
	Dental insurance										- 1				li li
	Dental subscription				H										lj lj
Health provision	Clinics														
	Hospitals	i									-				li li
	Dental centres	•			- H							<b>4</b>			lj lj
	Optical and audiology														li li
Aged care provision	Care homes				■3										lj li
	Retirement villages				11						;				į.

Spain:

Poland:

LUX MED

Sanitas Seguros

Sanitas Hospitales

and New Services

Sanitas Dental

Sanitas Mayores

#### Australia:

Bupa Health Insurance **Bupa Health Services** Bupa Villages and Aged Care Australia

#### **New Zealand:**

Bupa Villages and Aged Care New Zealand

#### **Bupa Hong Kong:**

Health insurance and provision

#### Mexico:

Türkiye:

Chile:

Brazil:

CarePlus

Bupa Chile

Bupa Acıbadem Sigorta

Bupa Mexico

#### IPMI:

Bupa Global Latin America

#### UK:

Bupa UK Insurance Bupa Dental Care Bupa Care Services **Bupa Health Services** 

#### India: Niva Bupa

#### IPMI:

Bupa Global

1.Global international insurance available in most countries. Includes 49% stake in Highway to Health (GeoBlue) in the US. 2. Bupa Arabia is an associate businesses.

3. In Spain we also have day care centres.

4. We also operate dental clinics in the Republic of Ireland managed through Bupa Global, India and UK

Full year 2024 results presentation

Bupa Arabia<sup>2</sup>, in which we have a 43.25% stake. We also have an interest MyClinic.

31

Saudi

Arabia:

Private

health

insurer,

# **Breakdown of borrowings**



	FY 2024 £m	HY 2024 £m	FY 2023 £m
£300m senior bond due 2024	-	-	299
£400m subordinated bond due 2026	400	400	399
£300m senior bond due 2027	274	268	268
€500m senior bond due 2030	426	442	447
£350m subordinated bond due 2035	348	348	347
Revolving credit facility	-	150	-
Bupa Chile borrowings	27	28	30
Other	56	59	46
Total borrowings	1,531	1,695	1,836
		1	
£300m subordinated perpetual Restricted Tier 1 <sup>1</sup>	297	297	297

1.Equity accounted

### **Disclaimer**

# Cautionary statement concerning forward-looking statements

This document may contain certain 'forward-looking statements'. Forward-looking statements often use words such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'forecasts', 'may', 'could', 'should', 'will', 'continue' or other words of similar meaning. Statements that are not historical facts, including statements about the beliefs and expectations of The British United Provident Association Limited (Bupa) and Bupa's directors or management, are forward-looking statements. In particular, but not exclusively, these may relate to Bupa's plans, current goals and expectations relating to future financial condition, performance and results.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur, many of which are beyond Bupa's control and all of which are solely based on Bupa's current beliefs and expectations about future events. These circumstances include, among others, global economic and business conditions, market-related risks such as fluctuations in interest rates and exchange rates, the policies and actions of governmental and regulatory authorities, risks arising out of health crises and pandemics, the impact of competition, the timing, impact and other uncertainties of future mergers or combinations within relevant industries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual future condition, results, performance or achievements of Bupa or its industry to be materially different to those expressed or implied by such forward-looking statements. Recipients should not place reliance on, and are cautioned against relying on, any forward-looking statements. Except as required by any laws and regulations, Bupa expressly disclaims any obligations or undertakings to release publicly any updates or revisions to any forward-looking statements to reflect any change in the expectations of Bupa with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Forward-looking statements in this document are current only as of the date on which such statements are made. No statement in this document is intended to be a profit forecast. Neither the content of Bupa's website nor the content of any other website accessible from hyperlinks on Bupa's website is incorporated into, or forms part of, this document.

The information contained in this presentation is intended to be read in conjunction with, and not as a substitute for, Bupa's full year statement for the twelve months ended 31 December 2024 (the "FY24 Report"). In the event of any inconsistency, the FY24 Report should be considered to prevail.